General Information

MaintermCHLOROMETHYL METHYL ETHER
Doc TypeNUL
CAS Reg.No.(or other ID)107-30-2
Regnum 173.20

From www.fda.gov

Computed Descriptors

Download SDF
2D Structure
CID7864
IUPAC Namechloro(methoxy)methane
InChIInChI=1S/C2H5ClO/c1-4-2-3/h2H2,1H3
InChI KeyXJUZRXYOEPSWMB-UHFFFAOYSA-N
Canonical SMILESCOCCl
Molecular FormulaC2H5ClO
Wikipediachloromethyl methyl ether

From Pubchem


Computed Properties

Property Name Property Value
Molecular Weight80.511
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count1
Rotatable Bond Count1
Complexity10.0
CACTVS Substructure Key Fingerprint A A A D c Y B A I A A E A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A E g I A A A A A A A A A A E I C A A A A B A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A = =
Topological Polar Surface Area9.2
Monoisotopic Mass80.003
Exact Mass80.003
XLogP3None
XLogP3-AA0.8
Compound Is CanonicalizedTrue
Formal Charge0
Heavy Atom Count4
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Isotope Atom Count0
Covalently-Bonded Unit Count1

From Pubchem


ADMET Predicted Profile --- Classification

Model Result Probability
Absorption
Blood-Brain BarrierBBB+0.9881
Human Intestinal AbsorptionHIA+1.0000
Caco-2 PermeabilityCaco2+0.6571
P-glycoprotein SubstrateNon-substrate0.8041
P-glycoprotein InhibitorNon-inhibitor0.9513
Non-inhibitor0.8428
Renal Organic Cation TransporterNon-inhibitor0.8538
Distribution
Subcellular localizationMitochondria0.5213
Metabolism
CYP450 2C9 SubstrateNon-substrate0.8149
CYP450 2D6 SubstrateNon-substrate0.8864
CYP450 3A4 SubstrateNon-substrate0.6467
CYP450 1A2 InhibitorNon-inhibitor0.6625
CYP450 2C9 InhibitorNon-inhibitor0.9037
CYP450 2D6 InhibitorNon-inhibitor0.9290
CYP450 2C19 InhibitorNon-inhibitor0.7518
CYP450 3A4 InhibitorNon-inhibitor0.9640
CYP Inhibitory PromiscuityLow CYP Inhibitory Promiscuity0.8997
Excretion
Toxicity
Human Ether-a-go-go-Related Gene InhibitionWeak inhibitor0.8602
Non-inhibitor0.9453
AMES ToxicityAMES toxic0.5548
CarcinogensCarcinogens 0.7808
Fish ToxicityLow FHMT0.6936
Tetrahymena Pyriformis ToxicityLow TPT0.9463
Honey Bee ToxicityHigh HBT0.7904
BiodegradationReady biodegradable0.6359
Acute Oral ToxicityIII0.4943
Carcinogenicity (Three-class)Danger0.6988

From admetSAR


ADMET Predicted Profile --- Regression

Model Value Unit
Absorption
Aqueous solubility0.2320LogS
Caco-2 Permeability1.4787LogPapp, cm/s
Distribution
Metabolism
Excretion
Toxicity
Rat Acute Toxicity1.8064LD50, mol/kg
Fish Toxicity2.7487pLC50, mg/L
Tetrahymena Pyriformis Toxicity-1.3239pIGC50, ug/L

From admetSAR


Toxicity Profile

Route of Exposure
Mechanism of Toxicity
Metabolism
Toxicity Values
Lethal Dose
Carcinogenicity (IARC Classification)1, carcinogenic to humans.
Minimum Risk Level
Health Effects
Treatment
Reference

From T3DB


Taxonomic Classification

KingdomOrganic compounds
SuperclassOrganic oxygen compounds
ClassOrganooxygen compounds
SubclassEthers
Intermediate Tree NodesNot available
Direct ParentDialkyl ethers
Alternative Parents
Molecular FrameworkAliphatic acyclic compounds
SubstituentsDialkyl ether - Hydrocarbon derivative - Organochloride - Organohalogen compound - Alkyl halide - Alkyl chloride - Aliphatic acyclic compound
DescriptionThis compound belongs to the class of organic compounds known as dialkyl ethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are alkyl groups.

From ClassyFire


Targets

General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1.
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Sipes NS, Martin MT, Kothiya P, Reif DM, Judson RS, Richard AM, Houck KA, Dix DJ, Kavlock RJ, Knudsen TB: Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95. doi: 10.1021/tx400021f. Epub 2013 May 16. [23611293 ]

From T3DB